Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?

Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?

Key PointsIovance Biotherapeutics has surged over the past year, but the stock is down by nearly 80% over the past five years.Past issues with dilution and disappointment may be clearing up, given recent sales growth and the company's current cash position.While still a high-risk play, there's much in Iovance's corner that may make it one of the more interesting opportunities right now among early-stage biotech stocks.10 stocks we like better th…